@article{32a68ea66f384b5e9aed39ae22dddb99,
title = "Corrigendum to Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis Kidney International Reports, Volume 8, Issue 1, January 2023, Pages 30–35 (Kidney International Reports (2023) 8(1) (30–35), (S2468024922018162), (10.1016/j.ekir.2022.10.004))",
abstract = "The authors regret that in Table 1, the mechanism of action for Atrasentan was incorrectly listed as “Dual ETA receptor/AT1 receptor antagonist.” The correct mechanism of action is “ETA receptor antagonist.” The authors would like to apologize for any inconvenience caused. DOI of original article: 10.1016/j.ekir.2022.10.004",
author = "{de Cos}, Marina and Kristin Meliambro and Campbell, {Kirk N.}",
note = "Publisher Copyright: {\textcopyright} 2023 International Society of Nephrology",
year = "2023",
month = apr,
doi = "10.1016/j.ekir.2023.01.026",
language = "English",
volume = "8",
pages = "949",
journal = "Kidney International Reports",
issn = "2468-0249",
publisher = "Elsevier Inc.",
number = "4",
}